On November 3, the opening ceremony of the headquarters base of Vives Medical was held in Phase 5 of Suzhou Biomedicine Industrial Park. Zheng Jie, founder and general manager of Vives Medical, Yin Jianguo, chairman of Suzhou Industrial Park Bioindustry Development Co., Ltd., Dong Chuan, chief investment officer of SDIC Chuanghe Fund Management Co., Ltd., Qian Xindong, chairman of Suzhou Yidelong Technology Co., Ltd., and Mark Roberts, European strategic partner of Vives, and other domestic and foreign guests and partners attended the ceremony.
Zheng Jie, founder of Vives Medical, delivered an opening speech and expressed his sincere gratitude to all partners who care about the development of Vives and help Vives grow.
He said that the opening of the new factory is an important milestone in the development history of Vives, and has laid a solid foundation for Vives to realize its vision of “making every heart beat healthily”. Vives’ new headquarters base will support the global market’s demand for AED and WCD products with a steady stream of innovative momentum and high-quality product production capacity, so that more lives can be saved!
Intelligent production helps Vivis Medical
Efficient production and quality assurance
The new headquarters base of Vivis Medical has a total area of 5,000 square meters, including intelligent warehousing, quality inspection, production workshops, administrative offices and other functional areas. The new production base has comprehensively improved the level of intelligence and production efficiency. From design to construction, it has introduced advanced production and manufacturing standards, and achieved standardized and refined management of the production process with a more scientific layout to meet the market demand for high-quality defibrillator products.
In addition, Vivis Medical Technology will also apply automated testing technology to further improve product quality. Through a digital testing system, the product is comprehensively tested and analyzed to ensure the quality stability of the product and provide users with more reliable products.
The commissioning of the new production base will provide strong support for the expansion of the company’s product production capacity, and will meet the production capacity requirements of 250,000 AEDs (automatic external defibrillators) and WCDs (wearable automatic external defibrillators) per year.
Build a complete ventricular arrhythmia product system
Meet clinical and market needs
Founded in 2019, Weiweisi is an innovative device service platform company focusing on the research and development of cardiac rhythm management medical devices and patient rhythm data services. In just 4 years, the company successfully obtained two NMPA registration certificates for automatic external defibrillators (AEDs).
In August this year, Weiweisi’s self-developed palm-sized AED was officially launched. The product breaks the core technology barriers, the front size is about the size of a smartphone, and the weight is less than 700g, successfully creating a mobile AED scene. Through the integrated collaborative layout of its fixed-position AED, mobile AED, and drone AED, Weiweisi pioneered the “air-ground integrated” AED three-dimensional rescue solution, which will significantly improve the efficiency of emergency treatment and the coverage efficiency of AED in my country.
Another core product of the company, WCD, mainly provides continuous protection for patients at high risk of short-term sudden cardiac death during the wearing period. It has entered the green channel for innovative medical device review in January 2021 and has now entered the human clinical stage.
In August 2022, VIS was successfully selected as the AI medical device innovation task unit with its “wearable automatic external defibrillator (WCD) and sudden death risk artificial intelligence assessment system”, becoming the main body of the innovation task, and is expected to break the import monopoly and fill the domestic gap.
In the future, VIS will gradually build a complete ventricular arrhythmia product system of semi-implantation + wearable + in vitro.
Practice the firm commitment of “making every heart beat healthily”
The new headquarters base will also become the base for VIS’s continuous innovation, providing better technical support and production environment for our innovative research and development, so as to promote the advent of more innovative products. Its opening provides VIS with a solid guarantee of production and manufacturing capabilities, which will become the cornerstone for us to better meet the needs of patients and customers.
